Biogen's $467 Million Trading Day Leads to 348th Ranking Despite 2.23% Stock Decline

On May 30, 2025, Biogen's trading volume reached $467 million, marking an 81.22% increase from the previous day, placing it 348th in the day's stock market rankings. Biogen's stock price fell by 2.23%.

Biogen has entered into a strategic collaboration with City Therapeutics to develop novel RNAi-based therapies. This partnership is significant as it leverages City Therapeutics' technology to expand Biogen's presence in the field of central nervous system (CNS) disease treatments. The collaboration involves Biogen paying City Therapeutics $46 million, which includes an upfront payment of $16 million and a $30 million investment. This venture is expected to usher in a new era for Biogen, targeting CNS diseases with an innovative RNAi approach. The collaboration is poised to transform the landscape of CNS disease treatments, highlighting the strategic importance of this partnership for Biogen's future prospects.